

# Mayur S. Parmar

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9561032/mayur-s-parmar-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22  
papers

236  
citations

10  
h-index

15  
g-index

38  
ext. papers

303  
ext. citations

3.6  
avg, IF

3.33  
L-index

#	Paper	IF	Citations
22	Body Mass Index (BMI): A Screening Tool Analysis.. <i>Cureus</i> , <b>2022</b> , 14, e22119	1.2	1
21	COVID-19 and Pregnancy: Risk, Symptoms, Diagnosis, and Treatment. <i>SN Comprehensive Clinical Medicine</i> , <b>2021</b> , 3, 1-7	2.7	8
20	Neurological Type Wilson Disease: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , <b>2021</b> , 3, 1946-1950	2.7	0
19	Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization. <i>AAPS PharmSciTech</i> , <b>2021</b> , 22, 172	3.9	9
18	Epidemiology, Pathogenesis, and Clinical Manifestations of Acute Esophageal Necrosis in Adults. <i>Cureus</i> , <b>2021</b> , 13, e16618	1.2	0
17	The Link Between Diabetes Mellitus and Tau Hyperphosphorylation: Implications for Risk of Alzheimer's Disease. <i>Cureus</i> , <b>2021</b> , 13, e18362	1.2	1
16	Current pharmacological approaches and potential future therapies for Celiac disease. <i>European Journal of Pharmacology</i> , <b>2021</b> , 909, 174434	5.3	1
15	SARS-CoV-2 and COVID-19: A Brief Review for Family Physicians. <i>Osteopathic Family Physician</i> , <b>2020</b> , 20-27	2.1	1
14	The Neurological Complexities and Prognosis of COVID-19. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-12	2.7	14
13	Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells. <i>Archives of Toxicology</i> , <b>2018</b> , 92, 669-677	5.8	13
12	Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1/2-dependent mechanism. <i>Journal of Nutritional Biochemistry</i> , <b>2018</b> , 54, 77-86	6.3	14
11	The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184262	3.7	12
10	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. <i>Neurobiology of Aging</i> , <b>2016</b> , 44, 159-172	5.6	39
9	Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. <i>Journal of Neuroscience</i> , <b>2016</b> , 36, 12425-12435	6.6	41
8	ERK1, 2, and 5 expression and activation in dopaminergic brain regions during postnatal development. <i>International Journal of Developmental Neuroscience</i> , <b>2015</b> , 46, 44-50	2.7	7
7	Curcumin, Hesperidin, and Rutin Selectively Interfere with Apoptosis Signaling and Attenuate Streptozotocin-Induced Oxidative Stress-Mediated Hyperglycemia. <i>Current Neurovascular Research</i> , <b>2015</b> , 12, 363-74	1.8	20
6	Role of ERK1, 2, and 5 in dopamine neuron survival during aging. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 669-79	5.6	19

5	Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure. <i>Brain Research</i> , <b>2014</b> , 1573, 37-43	3.7	14
4	Dicarboxylic Acid <b>2014</b> , 76-79		2
3	Methylglyoxal <b>2014</b> , 302-305		
2	Matrix metalloproteinase-9, -10, and -12, MDM2 and p53 expression in mouse liver during dimethylnitrosamine-induced oxidative stress and genomic injury. <i>Molecular and Cellular Biochemistry</i> , <b>2012</b> , 365, 351-61	4.2	12
1	Long term exposure effect of a unique metabolic nutrition system containing a diverse group of phytochemicals on serum chemistry and genomic and non-genomic changes in the liver of female B6C3F1 mice. <i>Phytotherapy Research</i> , <b>2008</b> , 22, 458-71	6.7	8